3D printing of medicines could lead to problems with identifying the patented drug product, attorneys warn

drug

The FDA’s approval of the first 3D-printed drug could lead to complicated product liability and intellectual property issues, attorneys told Bloomberg BNA recently.

The 3D printing of drugs products could lead to problems with identifying the patented drug product and with identifying who is considered the manufacturer for product liability purposes, the attorneys said. Continue reading “3D printing of medicines could lead to problems with identifying the patented drug product, attorneys warn”